Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription drugs. The company targets hospital acute care, gastroenterology, and oncology markets, primarily in the United States, with international distribution through partners. Its FDA-approved portfolio includes Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Sancuso for chemotherapy-induced nausea and vomiting, Vaprisol for hyponatremia, Vibativ for serious bacterial infections, and Talicia for H. pylori infection. Cumberland also develops ifetroban for Duchenne muscular dystrophy, systemic sclerosis, and idiopathic pulmonary fibrosis. The company was incorporated in 1999 and completed an initial public offering in 2009. In 2024, Cumberland agreed to sell its branded pharmaceutical line to Apotex.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - Specialty & Generic Homepage cumberlandpharma.com
Sector Healthcare IR page investor.cumberlandpharma.com
Tags
specialty pharmaceuticals, hospital acute care, gastroenterology, oncology, antibiotics, antiemetics, analgesics, laxatives, hyponatremia treatment, duchenne muscular dystrophy, pulmonary fibrosis, branded prescription drugs, Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, Talicia, ifetroban, Apotex, SciClone Pharmaceuticals, Tabuk Pharmaceutical Manufacturing Company, Perrigo Company, Vizient
Press page cumberlandpharma.com/news

Metrics

Valuation  
Market cap $ 117.394M
Market cap (USD) $ 117.394M
P/E -41.21
PEG —
P/BV 1.62
P/S 3.48
P/OCF 23.80
P/FCF 24.28
Dividend yield —
Turnover / mcap —
Returns  
ROE -11.9%
ROI -9.4%
ROIC -7.0%
Profit margin -6.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 21.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 121
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 44.521M 37.868M 39.553M 40.681M 35.045M 35.841M 45.553M 40.201M 1.6M 2M 900K 600K 32.027M 48.851M 51.143M 45.876M 43.537M 35.075M
Net profit -2.836M -6.48M -6.279M -5.57M -3.508M -3.339M -3.538M -6.963M -7.979M -944.683K 731.351K 2.424M -2.105M 5.842M 5.658M 2.457M 3.091M 4.766M
Free cash flow 4.835M -678.647K 5.813M 8.351M 6.239M 5.274M 2.81M 2.657M -833.674K 438.606K 5.734M 6.53M 648.714K 6.67M 8.465M -230.497K -196.832K 6.329M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 3.98 2.37 1.79 2.25 4.67 2.95 5.15 6.03 7.37 5.5 5.26 5.98 5.11 4.45 5.74 6.9 — —
Price performance 12m 0.68 0.32 -0.2 -0.52 0.58 -0.43 -0.15 -0.18 0.34 0.05 -0.12 0.17 0.15 -0.23 -0.17 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 7.33M 8.4M 7.84M 9.78M 12.4M 6.88M 13.2M 9.76M 11.7M 16.9M
↳ YoY growth +20.6% +14.5% -6.6% +24.7% +26.5% -44.4% +91.4% -25.9% +19.9% +44.8%
↳ 5y CAGR +0.7% +6.9% +11.6% +12.2% +15.3% -1.3% +9.4% +4.5% +3.6% +6.5%
Borrowings, current (USD) — — — — — — — 0.00 5.1M 0.00
Lease liabilities (USD) — — 3.8M 3M 2.08M 1.06M 4.76M 5.64M 5.3M 4.94M
Cash and deposits (USD) 34.5M 45.4M 27.9M 28.2M 24.8M 27M 19.8M 18.3M 18M 11.4M
Intangible assets (USD) 22.2M 21.4M 33.7M 30.9M 28.1M 24M 30.6M 22.6M 18M 14M
Right-of-use assets (USD) — — 3.6M 2.96M 2.03M 1.02M 5.22M 6.67M 6.18M 8.34M
Net debt (borrowings + leases - cash) (USD) — — — — — — — -12.7M -7.57M -6.5M
Cash flow detail
Operating cash flow (USD) 569,478 -557,714 3.11M 3.06M 5.42M 6.34M 8.45M 6.09M -612,186 4.93M
Purchases of property, plant and equipment (USD) -130,872 -275,960 -455,569 -246,202 -140,817 -103,532 -102,148 -281,268 -66,461 -97,903
Purchases of intangible assets (USD) -2M -1.21M -3.82M -772,944 -1.97M -250,930 -1.97M -171,783 -113,253 -84,402
Change in receivables (cash effect) (USD) -1.25M -1.06M 550,863 -1.94M -4.52M 5.5M -6.12M 3.4M -1.94M -5.24M
Change in inventories (cash effect) (USD) -1.1M -1.37M 460,505 2.86M 2.13M 4.82M 911,078 -23,143 2.41M 2.24M
Change in payables (cash effect) (USD) 191,901 2.31M 4.31M 1.82M 6.57M -757,591 14.5M 3.72M -991,359 6.71M
Share buybacks (cash effect) (USD) -2.52M -3.72M -2.88M -3.49M -1.85M -1.39M -1.05M -740,533 -579,049 -263,478
Interest paid (cash effect) (USD) -21,853 -14,993 -95,965 -198,661 -215,991 -63,978 -523,161 -647,137 -569,230 -441,677
Income taxes paid (cash effect) (USD) 8,359 -18,000 -15,441 -16,694 91,486 327 -3,300 -108,823 -15,000 3,525
Share-based compensation (USD) 852,102 1.12M 1.36M 1.49M 1.05M 741,867 447,503 365,040 301,895 408,320
Operating cash flow before change in receivables (USD) 1.82M 507,271 2.56M 4.99M 9.93M 842,076 14.6M 2.69M 1.33M 10.2M
Free cash flow (OCF - PPE - intangibles) (USD) -1.56M -2.05M -1.16M 2.04M 3.3M 5.99M 6.38M 5.64M -791,900 4.75M
Income detail
Research and development expense (USD) 3.19M 3.9M 7.32M 6.48M 5.77M 5.68M 6.69M 5.83M 4.82M 5.57M
↳ 5y CAGR -8.7% -5.2% +5.4% +13.8% +8.5% +12.2% +11.4% -4.4% -5.8% -0.7%
Total comprehensive income (USD) -944,683 -7.98M -6.96M -3.54M — — — — — —
Comprehensive income to owners (USD) -1M -8.05M -7.04M -3.55M — — — — — —
Reported Mar 13, 2017 Mar 9, 2018 May 15, 2019 Mar 20, 2020 Mar 12, 2021 Mar 11, 2022 Mar 13, 2023 Mar 7, 2025 Mar 7, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

$100 million Strategic Transaction Closed

Plans to Submit New Drug Application for Ifetroban in DMD

Top-Line Results Announced for Systemic Sclerosis Trial

NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today its third quarter 2026 financial results and provided a company update. Cumberland has announced its decision to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ifetroban as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”).

The third quarter of 2026 marked Cumberland’s first period of operations following the July 1, 2026, closing of its Strategic Transaction with Apotex Health, the largest pharmaceutical company based in Canada. Cumberland’s commercial brands and organization were integrated into Apotex’s U.S. branded business. The $100 million in proceeds at closing strengthened the company’s balance sheet, simplified its business model and allowed Cumberland to concentrate its resources on its clinical pipeline.

November 3, 2026

PDF Version 113.8 KB

NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.(Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with third quarter 2026 financial results after the market closes on Tuesday, Nov. 10, 2026.

A conference call will be held on Nov. 10 at 4:30 p.m. Eastern Time to discuss the results and update.

Call Participation

The link to register is https://register-conf.media-server.com/register/BI0050c03d0ef44b49b8905264f4232aef.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/nbwu96yx.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

NASHVILLE, Tenn. (Oct. 26, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), (“Cumberland” or the “Company”) an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”). The Company announced plans to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ifetroban as a potential treatment for the cardiomyopathy associated with DMD.

Cumberland requested a pre-NDA meeting with FDA, which was held this fall. During the pre-NDA meeting, the discussions primarily involved the content and format of the planned submission. Cumberland is proposing the FIGHT DMD™ trial as the pivotal study to be combined with comparison data from two natural history databases to support product approval. Following the meeting FDA granted the Company's request for rolling submission of the NDA, which allows completed sections of the application to be provided to the FDA for review, prior to the submission of the entire application.

Prompts

Cumberland Pharmaceuticals Inc. (ticker CPIX), listed in United States.

ETFs Holding Cumberland Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 56,305 $ 373.302K Nov 12, 2026
DFSU 0.00% 2,780 $ 18.431K Nov 12, 2026
DFAT 0.00% 9,341 $ 61.931K Nov 12, 2026
DFAC 0.00% 8,635 $ 57.25K Nov 12, 2026
DXUV 0.00% 436 $ 2,890.68 Nov 12, 2026
AVSC 0.00% 3,758 $ 19.579K Nov 16, 2026